Anti-Obesity Drug Discovery and Development

Anti-Obesity Drug Discovery and Development

Volume: 1

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory, Scopus

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Development of Melanin Concentrating Hormone Receptor R1 Antagonists for the Pharmacological Treatment of Obesity

Pp. 200-228 (29)

Gildardo Rivera, Antonio Monge and Virgilio Bocanegra-Garcia

Abstract

In this chapter we review the development of melanin concentrating hormone receptor 1 (MCH-R1) antagonists as a new perspective for the pharmacological treatment of obesity. We will initially focus on melanin concentrating hormone (MCH): structure, localization and function in the regulation of feeding behavior and energy balance and two receptors for MCH in humans. We will then review the discovery of the first MCH-R1 antagonists, the drug-design strategies used to obtained new series of MCH-R1 antagonists and an analysis of their structure-activity relationship. Finally, we will evaluate the absorption, distribution, metabolism and excretion, efficacy, safety and toxicity in preclinical and clinical trials.

Keywords:

Development, Melanin concentrating hormone (MCH), Melanin concentrating hormone receptor 1 (MCH-R1), Structure-activity relationship (SAR), Obesity.

Affiliation:

Departamento de Farmacia y Quimica Medicinal, Unidad Academica Multidisciplinaria Reynosa Aztlan, Universidad Autonoma de Tamaulipas, Calle 16 y Lago de Chapala, s/n, 88740, Reynosa, Mexico.